Schemata of the systematic review.

<p>Schemata of the systematic review.</p

Enhancer of Zeste Homolog 2 as an Independent Prognostic Marker for Cancer: A Meta-Analysis

<div><p>Background</p><p>Novel biomarkers are of particular interest for predicting cancer prognosis. This study aimed to explore the associations between enhancer of zeste homolog 2 (EZH2) and patient survival in various cancers.</p><p>Methods</p><p>Relevant literature was retrieved from PubMed and Web of Science databases. Pooled hazard ratios (HRs), odds ratios (ORs), and 95% confidence intervals (CIs) were calculated.</p><p>Results</p><p>Forty-nine studies (8,050 patients) were included. High EZH2 expression was significantly associated with shorter overall (hazard ratio [HR] 1.74, 95% CI: 1.46–2.07), disease-free (HR 1.59, 95% CI: 1.27–1.99), metastasis-free (HR 2.19, 95% CI: 1.38–3.47), progression-free (HR 2.53, 95% CI: 1.52–4.21), cancer-specific (HR 3.13, 95% CI: 1.70–5.74), and disease-specific (HR 2.29, 95% CI: 1.56–3.35) survival, but not recurrence-free survival (HR 1.38, 95% CI: 0.93–2.06). Moreover, EZH2 expression significantly correlated with distant metastasis (OR 3.25, 95% CI: 1.07–9.87) in esophageal carcinoma; differentiation (OR 3.00, 95% CI: 1.37–6.55) in non-small cell lung cancer; TNM stage (OR 3.18, 95% CI: 2.49–4.08) in renal cell carcinoma; and histological grade (OR 4.50, 95% CI: 3.33–6.09), estrogen receptor status (OR 0.15, 95% CI: 0.11–0.20) and progesterone receptor status (OR 0.30, 95% CI: 0.23–0.39) in breast cancer.</p><p>Conclusions</p><p>Our results suggested that EZH2 might be an independent prognostic factor for multiple survival measures in different cancers.</p></div

Results of subgroup analysis of the association between nuclear EZH2 expression and DFS and RFS of multiple cancers.

<p>DFS: disease-free survival; RFS: recurrence-free survival; HR: hazard ratio.</p><p>Results of subgroup analysis of the association between nuclear EZH2 expression and DFS and RFS of multiple cancers.</p

Results of the meta-analysis of increased EZH2 expression and clinicopathological features of four types of cancer.

<p>OR: odds ratio; ER: estrogen receptor; PR: progesterone receptor; Her-2: human epidermal growth factor receptor 2.</p><p>Results of the meta-analysis of increased EZH2 expression and clinicopathological features of four types of cancer.</p

Schemata of the systematic review.

<p>Schemata of the systematic review.</p

Forest plot for the meta-analysis of the association between EZH2 expression and overall survival in various cancer types.

<p>The segments represent the 95% confidence intervals (CIs) of each study. The diamond represents the overall effect size, and the diamond’s width represents the overall 95% CI.</p

Forest plots for the accumulative meta-analyses of the association between EZH2 expression and cancer survival.

<p>The following cancer survival measures were analyzed: OS (A), DFS (B), and RFS (C). The segments represent the 95% confidence intervals (CIs) of each study. The diamond represents the overall effect size, and the diamond’s width represents the overall 95% CI.</p